1. Design, Synthesis and Bioactive Evaluation of Topo I/ c-MYC Dual Inhibitors to Inhibit Oral Cancer via Regulating the PI3K/AKT/NF-κB Signaling Pathway.
- Author
-
Zheng B, Wang YX, Wu ZY, Li XW, Qin LQ, Chen NY, Su GF, Su JC, and Pan CX
- Subjects
- Humans, Animals, Cell Line, Tumor, Mice, Proto-Oncogene Proteins c-myc metabolism, Proto-Oncogene Proteins c-myc genetics, Apoptosis drug effects, Molecular Docking Simulation, Antineoplastic Agents pharmacology, Antineoplastic Agents chemical synthesis, Antineoplastic Agents chemistry, Xenograft Model Antitumor Assays, NF-kappa B metabolism, NF-kappa B antagonists & inhibitors, Proto-Oncogene Proteins c-akt metabolism, Mouth Neoplasms drug therapy, Mouth Neoplasms pathology, Mouth Neoplasms metabolism, Signal Transduction drug effects, Phosphatidylinositol 3-Kinases metabolism, Topoisomerase I Inhibitors pharmacology, Topoisomerase I Inhibitors chemical synthesis, Topoisomerase I Inhibitors chemistry, DNA Topoisomerases, Type I metabolism, Drug Design, Cell Proliferation drug effects
- Abstract
The significantly rising incidence of oral cancer worldwide urgently requires the identification of novel, effective molecular targets to inhibit the progression of malignancy. DNA topoisomerase I (Topo I) is a well-established target for cancer treatment, and many studies have shown that different cancer cell genes could be targeted more selectively with one type of Topo I inhibitor. In this report, a new scaffold pyridothieno[3,2- c ]isoquinoline 11,11-dioxide was designed via the combination of the key fragment or bioisoster of Topo I inhibitor azaindenoisoquinolines and G-quadruplex binder quindoline. Thirty-two target derivatives were synthesized, among which compounds 7be, with potent Topo I inhibition, exhibited effective antiproliferative activity against Cal27, one of the oral cancer cell lines highly expressing Topo I protein. Further studies indicated that 7be could also inhibit the activation of PI3K/AKT/NF-κB pathway and downregulate the level of c-MYC, repress the colony formation and the migration of Cal27 cells and trigger apoptosis and autophagy. Molecular docking indicated that 7be could interact with the complex of Topo I and DNA via a mode similar to the indenoisoquinolines. The results of the Cal27 xenograft model confirmed that 7be exhibited promising anticancer efficacy in vivo, with tumor growth inhibition (TGI) of 64.7% at 20 mg/kg.
- Published
- 2025
- Full Text
- View/download PDF